Custom Search

Brand Name(s): Simulect
CAS nš: 152923-56-3
(ba sil ik si mab)

What is Basiliximab?

Basiliximab belongs to a group of medicines known as immunosuppressive agents. It is used to lower the body's natural immunity in patients who receive kidney transplants.

When a patient receives a kidney transplant, the body's white blood cells will try to get rid of (reject) the transplanted kidney. This medicine works by preventing the white blood cells from getting rid of the transplanted kidney. The effect of this medicine on the white blood cells may also reduce the body's ability to fight infections.

See more Product Info

Latest News

Antibody Reduces Rejection in High-risk Kidney Transplants

Nearly 70 percent of kidney transplant patients get short-term drug therapy initially administered...

[more]

Induction therapy post-heart transplantation with basiliximab is safer than muromonab

In a recent heart transplantation study, induction therapy with basiliximab was safer and better...

[more]

Cerimon licenses Novartis bowel disease drug

Cerimon Pharmaceuticals has licensed the exclusive worldwide rights from Novartis Pharma to develop...

[more]

Cerimon Pharmaceuticals Licenses Exclusive Worldwide Rights to Simulect(R) for the Treatment of Inflammatory Bowel Disease

South San Francisco, Calif. -- Cerimon Pharmaceuticals, Inc. announced today that it has licensed...

[more]

Basiliximab Plus Tacrolimus Reduce Liver Transplant Rejection, Increase Survival

Basiliximab in a tacrolimus-based immunosuppressive regimen is effective in reducing incidences of...

[more]

Use of this site is subject to the following terms of use